Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLOTIRI gastric cancer trial
2009-014895-23Phase 4Terminated
- Sponsor
- Universitätsklinikum Erlangen
- Start
- Jan 2013
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fluorouracil, folinic acid, oxaliplatin, docetaxel and irinotecan in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Universitätsklinikum Erlangen. Primary endpoint: Median survival. Started Jan 2013; status: terminated.
02
Drugs
fluorouracilfolinic acidoxaliplatindocetaxelirinotecan
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2009-014895-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014895-23.